PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)
PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]
Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025
The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]
“Smart” Radiation Gets Smarter — Lutetium-177 Therapy Expands Its Reach
A treatment once reserved for men who had exhausted nearly every other option is now available earlier in the course […]
A New Standard in Detection — PSMA PET Imaging Is Changing How We Find Prostate Cancer
For decades, diagnosing and staging prostate cancer relied on a combination of CT scans, bone scans, and MRI. That picture […]
June 2026
Includes: Study finds prostate cancer overdiagnosis rises sharply with age, experimental drug shows promise for patients with advanced prostate cancer,